Hypothesis

Persistent expression of red‑shifted microbial opsins such as ChRoME or CatCh in surviving retinal neurons drives a sustained intracellular calcium load that activates calpain‑mediated proteolysis of synaptic proteins, thereby eroding the functional benefit of optogenetic vision restoration over months.

Mechanistic Rationale

• Red‑shifted channelrhodopsins were engineered for high light sensitivity and calcium permeability to enable ganglion‑cell activation within ocular safety limits [5].
• Calcium influx through these opsins is not limited to the brief phototransduction window; continuous low‑level light exposure in ambient environments yields a tonic calcium rise.
• Elevated cytosolic calcium triggers calpain proteases, which cleave key synaptic scaffolding proteins (e.g., PSD‑95, synaptophysin) and voltage‑gated channel subunits, compromising synaptic fidelity.
• This proteolytic cascade parallels observations in neurodegenerative models where chronic calcium dysregulation precedes synaptic loss, independent of cell death.
• Human opsin chimeras reduce immune reactivity [2] but retain the calcium‑permeable pore, suggesting the calcium‑dependent mechanism is orthogonal to immunogenicity.
• Preliminary data show MCO‑010 preserves photoreceptor structure in rd1/rd10 models beyond functional rescue [4]; however, long‑term electrophysiological stability of transduced bipolar or ganglion cells remains untested.

Testable Predictions

1. Animals expressing ChRoME or CatCh will exhibit higher baseline intracellular calcium in transduced neurons compared to controls expressing a calcium‑impermeable opsin (e.g., Jaws) or a human opsin chimera.
2. Elevated calpain activity will correlate with reduced synaptic protein levels in the inner retina at 3‑ and 6‑month post‑injection points.
3. Co‑expression of a calcium buffer (e.g., parvalbumin) or targeted expression of the opsin to subcellular compartments lacking synaptic machinery will attenuate calcium accumulation, preserve synaptic proteins, and extend the duration of visual‑behavioral improvement.
4. Pharmacological inhibition of calpain (e.g., with MDL‑28170) will rescue synaptic protein loss and prolong functional gains without altering opsin expression levels.

Experimental Design

• Model: rd10 mice receiving intravitreal AAV2‑ChRoME‑GRM6 (bipolar‑cell promoter) or AAV2‑CatCh‑GfaABC1D (Müller‑cell promoter) vectors; parallel groups receive AAV2‑Jaws‑GRM6 or a human opsin chimera.
• Readouts:
  • In vivo two‑photon calcium imaging (GCaMP6f) to quantify resting and light‑evoked calcium transients in transduced cells.
  • Western blot and immunohistochemistry for calpain‑cleaved spectrin (SBDP145) and synaptic proteins (PSD‑95, synaptophysin) at 1, 3, 6 months.
  • Optomotor response and visual‑evoked potential assays to track functional vision over time.
  • ELISA for inflammatory cytokines to ensure any differences are not driven by immune activation.
• Intervention arms: (a) co‑inject AAV‑parvalbumin, (b) treat with systemic calpain inhibitor, (c) vehicle control.
• Statistical analysis: Mixed‑effects models accounting for repeated measures; power analysis targeting 80% detection of a 30% difference in synaptic protein levels.

Falsifiability

If chronic calcium elevation is not a limiting factor, then (i) calcium levels in opsin‑expressing cells will remain comparable to controls, (ii) calpain activity and synaptic protein degradation will not differ between groups, and (iii) buffering calcium or inhibiting calpain will not extend the duration of visual improvement beyond that achieved by opsin expression alone. Observing any of these outcomes would refute the hypothesis.